Ultra-Low Dose Rituximab Controls Disease Activity for Most RA Patients in New Study

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows the majority of rheumatoid arthritis patients on an ultra-low dose of rituximab maintained low disease activity for up to 4 years, and rarely needed to switch to other biologic drugs.

Black Patients with RA Less Likely to Receive a Biologic, More Likely to Be Treated with Glucocorticoids Than Whites

A new study reveals that Black patients with rheumatoid arthritis were less likely to be prescribed a biologic treatment and more likely to use glucocorticoids, which carry a risk of serious long-term side effects. This study highlights ongoing racial disparities in the care of patients with rheumatic disease. Details of the study was shared at ACR Convergence, the American College of Rheumatology’s annual meeting.